# "MIRO" Molecularly Oriented Immuno-radio-therapy

> **NCT02710643** · PHASE2 · COMPLETED · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 110 (actual)

## Conditions studied

- Follicular Lymphoma, Grade 1
- Follicular Lymphoma, Grade 2
- Follicular Lymphoma Grade 3A

## Interventions

- **DRUG:** OFATUMUMAB

## Key facts

- **NCT ID:** NCT02710643
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2018-04
- **Final completion:** 2022-04-07
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2022-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02710643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02710643, ""MIRO" Molecularly Oriented Immuno-radio-therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02710643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*